Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb Ixempra gets FDA approval
The FDA has also granted approval of Ixempra in combination with capecitabine for the treatment of patients with metastatic breast cancer resistant to treatment with an anthracycline, and
The FDA has also granted approval of Ixempra in combination with capecitabine for the treatment of patients with metastatic breast cancer resistant to treatment with an anthracycline, and
The two Phase III pivotal trials assessed the safety and efficacy of a six-month course of Puricase therapy in patients with treatment-failure gout, under the auspices of a
The agreement has an initial five-year term that can be terminated earlier by either party on six months notice and automatically renews for successive two-year terms unless terminated
For the option, Cubist will pay $4.7 million and also will pay approximately $1 million for Illumigen’s operating costs during the option period and for an IND-enabling study
A total of 41,509,214 common shares were deposited by shareholders of Orthosoft. This represents, with shares held by Zimmer or its affiliates, 91.31% of the 52,392,755 outstanding Shares.
Isis has granted an exclusive worldwide license to Altair for the development and commercialization of ISIS 369645, an inhaled inhibitor of the IL-4/IL-13 signaling pathways for the treatment
Consummation of the transaction remains subject to customary closing conditions, including clearance from antitrust authorities in Portugal and Turkey. The initial review periods in both of these jurisdictions
The iX range of afterloaders will be officially introduced at the annual American Society of Therapeutic Radiation Oncologists exhibition in Los Angeles on October 29, 2007. At the
Dr Bair has over 25 years of management experience in oncology drug discovery, development and chemistry. Prior to joining EntreMed, Dr Bair served as senior vice president and
The agreement provides an opportunity for Baxter to exclusively develop a new recombinant protein and investigate its potential use in treating unmet medical needs. Under the terms of